A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification

Matteo Dugo, Gabriella Nicolini, Gabrina Tragni, Ilaria Bersani, Antonella Tomassetti, Valentina Colonna, Michele Del Vecchio, Filippo De Braud, Silvana Canevari, Andrea Anichini, Marialuisa Sensi

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Dysregulation of receptor tyrosine kinases (RTKs) contributes to several aspects of oncogenesis including drug resistance. In melanoma, distinct RTKs have been involved in BRAF inhibitors (BRAFi) resistance, yet the utility of RTKs expression pattern to identify intrinsically resistant tumors has not been assessed. Transcriptional profiling of RTKs and integration with a previous classification, reveals three robust subtypes in two independent datasets of melanoma cell lines and one cohort of melanoma samples. This classification was validated by Western blot in a panel of patient-derived melanoma cell lines. One of the subtypes identified here for the first time displayed the highest and lowest expression of EGFR and ERBB3, respectively, and included BRAF-mutant tumors all intrinsically resistant to BRAFi PLX4720, as assessed by analysis of the Cancer Cell Line Encyclopedia pharmacogenomic study and by in vitro growth inhibition assays. High levels of EGFR were detected, even before therapy, in tumor cells of one of three melanoma patients unresponsive to BRAFi. Use of different pharmacological inhibitors highlighted the relevance of PI3K/mTOR signaling for growth of this PLX4720-resistant subtype. Our results identify a specific molecular profile of melanomas intrinsically resistant to BRAFi and suggest the PI3K/ mTOR pathway as a potential therapeutic target for these tumors.

Original languageEnglish
Pages (from-to)5118-5133
Number of pages16
JournalOncotarget
Volume6
Issue number7
Publication statusPublished - 2015

Fingerprint

Receptor Protein-Tyrosine Kinases
Melanoma
Genes
Neoplasms
Phosphatidylinositol 3-Kinases
Cell Line
Encyclopedias
Growth
Drug Resistance
Carcinogenesis
Western Blotting
Pharmacology
Therapeutics

Keywords

  • BRAF
  • BRAF inhibitors
  • Drug resistance
  • Melanoma subtypes
  • Receptor tyrosine kinases

ASJC Scopus subject areas

  • Oncology

Cite this

A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification. / Dugo, Matteo; Nicolini, Gabriella; Tragni, Gabrina; Bersani, Ilaria; Tomassetti, Antonella; Colonna, Valentina; Vecchio, Michele Del; Braud, Filippo De; Canevari, Silvana; Anichini, Andrea; Sensi, Marialuisa.

In: Oncotarget, Vol. 6, No. 7, 2015, p. 5118-5133.

Research output: Contribution to journalArticle

@article{f0086abb86bf45588d00dff9b3be6f1e,
title = "A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification",
abstract = "Dysregulation of receptor tyrosine kinases (RTKs) contributes to several aspects of oncogenesis including drug resistance. In melanoma, distinct RTKs have been involved in BRAF inhibitors (BRAFi) resistance, yet the utility of RTKs expression pattern to identify intrinsically resistant tumors has not been assessed. Transcriptional profiling of RTKs and integration with a previous classification, reveals three robust subtypes in two independent datasets of melanoma cell lines and one cohort of melanoma samples. This classification was validated by Western blot in a panel of patient-derived melanoma cell lines. One of the subtypes identified here for the first time displayed the highest and lowest expression of EGFR and ERBB3, respectively, and included BRAF-mutant tumors all intrinsically resistant to BRAFi PLX4720, as assessed by analysis of the Cancer Cell Line Encyclopedia pharmacogenomic study and by in vitro growth inhibition assays. High levels of EGFR were detected, even before therapy, in tumor cells of one of three melanoma patients unresponsive to BRAFi. Use of different pharmacological inhibitors highlighted the relevance of PI3K/mTOR signaling for growth of this PLX4720-resistant subtype. Our results identify a specific molecular profile of melanomas intrinsically resistant to BRAFi and suggest the PI3K/ mTOR pathway as a potential therapeutic target for these tumors.",
keywords = "BRAF, BRAF inhibitors, Drug resistance, Melanoma subtypes, Receptor tyrosine kinases",
author = "Matteo Dugo and Gabriella Nicolini and Gabrina Tragni and Ilaria Bersani and Antonella Tomassetti and Valentina Colonna and Vecchio, {Michele Del} and Braud, {Filippo De} and Silvana Canevari and Andrea Anichini and Marialuisa Sensi",
year = "2015",
language = "English",
volume = "6",
pages = "5118--5133",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "7",

}

TY - JOUR

T1 - A melanoma subtype with intrinsic resistance to BRAF inhibition identified by receptor tyrosine kinases gene-driven classification

AU - Dugo, Matteo

AU - Nicolini, Gabriella

AU - Tragni, Gabrina

AU - Bersani, Ilaria

AU - Tomassetti, Antonella

AU - Colonna, Valentina

AU - Vecchio, Michele Del

AU - Braud, Filippo De

AU - Canevari, Silvana

AU - Anichini, Andrea

AU - Sensi, Marialuisa

PY - 2015

Y1 - 2015

N2 - Dysregulation of receptor tyrosine kinases (RTKs) contributes to several aspects of oncogenesis including drug resistance. In melanoma, distinct RTKs have been involved in BRAF inhibitors (BRAFi) resistance, yet the utility of RTKs expression pattern to identify intrinsically resistant tumors has not been assessed. Transcriptional profiling of RTKs and integration with a previous classification, reveals three robust subtypes in two independent datasets of melanoma cell lines and one cohort of melanoma samples. This classification was validated by Western blot in a panel of patient-derived melanoma cell lines. One of the subtypes identified here for the first time displayed the highest and lowest expression of EGFR and ERBB3, respectively, and included BRAF-mutant tumors all intrinsically resistant to BRAFi PLX4720, as assessed by analysis of the Cancer Cell Line Encyclopedia pharmacogenomic study and by in vitro growth inhibition assays. High levels of EGFR were detected, even before therapy, in tumor cells of one of three melanoma patients unresponsive to BRAFi. Use of different pharmacological inhibitors highlighted the relevance of PI3K/mTOR signaling for growth of this PLX4720-resistant subtype. Our results identify a specific molecular profile of melanomas intrinsically resistant to BRAFi and suggest the PI3K/ mTOR pathway as a potential therapeutic target for these tumors.

AB - Dysregulation of receptor tyrosine kinases (RTKs) contributes to several aspects of oncogenesis including drug resistance. In melanoma, distinct RTKs have been involved in BRAF inhibitors (BRAFi) resistance, yet the utility of RTKs expression pattern to identify intrinsically resistant tumors has not been assessed. Transcriptional profiling of RTKs and integration with a previous classification, reveals three robust subtypes in two independent datasets of melanoma cell lines and one cohort of melanoma samples. This classification was validated by Western blot in a panel of patient-derived melanoma cell lines. One of the subtypes identified here for the first time displayed the highest and lowest expression of EGFR and ERBB3, respectively, and included BRAF-mutant tumors all intrinsically resistant to BRAFi PLX4720, as assessed by analysis of the Cancer Cell Line Encyclopedia pharmacogenomic study and by in vitro growth inhibition assays. High levels of EGFR were detected, even before therapy, in tumor cells of one of three melanoma patients unresponsive to BRAFi. Use of different pharmacological inhibitors highlighted the relevance of PI3K/mTOR signaling for growth of this PLX4720-resistant subtype. Our results identify a specific molecular profile of melanomas intrinsically resistant to BRAFi and suggest the PI3K/ mTOR pathway as a potential therapeutic target for these tumors.

KW - BRAF

KW - BRAF inhibitors

KW - Drug resistance

KW - Melanoma subtypes

KW - Receptor tyrosine kinases

UR - http://www.scopus.com/inward/record.url?scp=84925002882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925002882&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84925002882

VL - 6

SP - 5118

EP - 5133

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 7

ER -